View Author
patient group myeloid leukemia survival treatment leukemia study cycle cytarabine cytogenetic response myeloid remission university square meter blood chemotherapy donor therapy induction imatinib result table effect hospital death factor center month event-free survival g-csf cytogenetic response daunorubicin square meter event-free relapse value number analysis abnormality erasmus university erasmu trial outcome high-dose level ratio netherland phase combination therapy nejm.org escalated-dose group 60 years combination recovery psc -833 performance status cancer hematologic england journal disease-free survival conventional-dose group society disease-free -833 copyright event massachusett e ng l category status erasmus mc performance high-dose cytarabine monosomal karyotype resistance count right cytogenetic findings
8 Most Recent Publications
|
Cytarabine dose for acute myeloid leukemia
(Article)
Löwenberg, B. Pabst, T. Greef, G.E. de Verdonck, L.F. Schaafsma, M.R. Gregor, M. Theobald, M. Schanz, U. Maertens, J. Ossenkoppele, G.J. Vellenga, E. Putten, W. van Schouten, H.C. Graux, C. Ferrant, A. Sonneveld, P. Biemond, B.J. Gratwohl, A. |
2011-03-17
|
|
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
(Article)
Deenik, W. Janssen, J.J.W.M. Sonneveld, P. Marwijk Kooy, M. van Wittebol, S. Willemze, R. Wijermans, P.W. Beverloo, H.B. Löwenberg, B. Valk, P.J.M. Ossenkoppele, G.J. Cornelissen, J.J. Holt, B. van der Verhoef, G.E.G. Smit, W.M. Kersten, M.J. Daenen, S.M.G.J. Verdonck, L.F. Ferrant, A. Schattenberg, A.V.M.B. |
2010-06-01
|
|
Gemtuzumab ozogamicin as postremission treatment inAMLat 60 years of age or more: results of a multicenter phase 3 study
(Article)
Löwenberg, B. Beck, J.A. Biemond, B.J. Vellenga, E. Breems, D.A. Muijnck, H. de Schaafsma, R. Verhoef, G. Döhner, H. Gratwohl, A. Pabst, T. Ossenkoppele, G.J. Graux, C. Maertens, J. Putten, W.L.J. van Schouten, H.C. Verdonck, L.F. Ferrant, A. Sonneveld, P. Jongen-Lavrencic, M. Lilienfeld-Toal, M. Von |
2010-04-01
|
|
High-dose daunorubicin in older patients with acute myeloid leukemia
(Article)
Löwenberg, B. Ossenkoppele, G.J. Biemond, B.J. Vellenga, E. Marwijk Kooy, M. van Verdonck, L.F. Beck, J.A. Döhner, H. Gratwohl, A. Pabst, T. Verhoef, G.E.G. Putten, W.L.J. van Schouten, H.C. Graux, C. Ferrant, A. Sonneveld, P. Maertens, J. Jongen-Lavrencic, M. Lilienfeld-Toal, M. Von |
2009-09-24
|
|
Dose-finding study of imatinib in combination with intravenous cytarabine: Feasibility in newly diagnosed patients with chronic myeloid leukemia
(Article)
Deenik, W. Holt, B.D. van Sonneveld, P. Kooy, M.M. van Wittebol, S. Willemze, R. Wijermans, P.W. Westveer, P.H.M. Beverloo, H.B. Valk, P.J.M. Löwenberg, B. Ossenkoppele, G.J. Verhoef, G.E.G. Cornelissen, J.J. Smit, W.M. Kersten, M.J. Kluin-Nelemans, H.C. Verdonck, L.F. Ferrant, A. Schattenberg, A.V.M.B. Janssen, J.J.W.M. |
2008-03-01
|
|
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom?
(Article)
Cornelissen, J.J. Putten, W.L.J. van Lelie, H. van der Fey, M. Ferrant, A. Maertens, J. Gratwohl, A. Löwenberg, B. Verdonck, L.F. Theobald, M. Jacky, E. Daenen, S.M.G.J. Marwijk Kooy, M. van Wijermans, P.W. Schouten, H. Huijgens, P.C. |
2007-05-01
|
|
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
(Article)
Holt, B. van der Verhoef, G.E.G. Knauf, W.U. Dugan, M. Shepherd, J. Piccaluga, P.P. Ossenkoppele, G.J. Vellenga, E. Ferrant, A. Fey, M.F. Crump, M. Theobald, M. Sonneveld, P. Selleslag, D. Löwenberg, B. Burnett, A.K. |
2005-01-01
|
|
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia
(Article)
Löwenberg, B. Kovacsovics, T. Daenen, S.M.G.J. Ferrant, A. Gratwohl, A. Greef, G.E. de Putten, W.L.J. van Theobald, M. Gmur, J. Boogaerts, M. Verdonck, L.F. Sonneveld, P. Fey, M.F. Huijgens, P. |
2003-01-01
|
